o9 Solutions to supply AI-powered IBP platform to Samsung Bioepis

• A major project to manage Samsung Bioepis’ global supply chain using o9’s IBP platform is underway.
• Scenario planning features will enable timely responses to market and operational challenges.
• This can be swiftly applied to all phases of short-, medium-, and long-term planning.

January 18th, 2021 – Seoul, Korea – o9 Solutions, a premier AI-powered IBP platform provider, announced that it would supply its next-generation platform to Samsung Bioepis Co., Ltd., bolstering the management of its biopharmaceutical product manufacturing and supply chain. o9 Solutions’ platform will also help Samsung Bioepis optimize its focus on development, clinical trial management, and regulatory registration.

o9 Solutions’ unique platform, or ‘digital brain’, supports all planning phases, including long-term strategic planning to medium- and short-term execution. The platform will be integrated into the client’s existing enterprise resource planning (ERP), seamlessly providing efficiencies in supply chain management, financial management, and collaboration.

The integration of o9 Solutions’ digital brain into Samsung Bioepis will allow the company to leverage AI and analytics to streamline commercial planning, revenue planning, and gap closure activities. This conversion of data into knowledge will enable a better understanding of how best to drive initiatives from new products to marketing and pricing for incremental impact and an optimal mix of investment.

Chakri Gottemukkala, CEO of o9 Solutions, said, “Our SCM platform contract with Samsung Bioepis is o9 Solutions’ first project with a biopharmaceutical company, and we are very honored. We will be actively supporting Samsung Bioepis in its efforts to enhance productivity and reduce costs by providing our solutions to manage and plan pharmaceutical manufacturing and distribution.”

In a world of volatility, APEX is the answer

The AI-powered operating model that helps enterprises thrive in the VUCA era. The o9 Digital Brain unifies planning, forecasting, and execution — powered by AI.

Learn more

About Samsung Bioepis

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media– Twitter, LinkedIn.

Future-proof business solutions with GenAI

Supercharge planning and decisions with GenAI’s intelligent insights. See how it transforms your business.

Request a demo

resources

View our related resources

[news]

o9 is Recognized in the 2025 Gartner® Critical Capabilities for Supply Chain Planning Solutions

[news]

o9 Welcomes AI visionary Dr. Ashwin Rao as Executive Vice President, Next-Gen AI and Technology, to Drive the Future of Enterprise Planning and Decisioning

[news]

o9 Announces Winners of Its APAC Partner Awards at aim10x Asia 2025

[news]

o9 joins Catena-X Community to Advance Standard-Based Collaboration in Automotive Supply Chains

[news]

o9 Partners With JD Sports Fashion to Optimize Assortment Planning for Scalable Growth

[news]

o9 is Raising the Bar for Enterprise Planning and Execution

[news]

o9 Delivers Strong Q3 2025 with 30-Plus Global Go-Lives and Record Attendance at Its aim10x Americas Summit

[news]

o9 Receives the Platinum Medal by EcoVadis, Ranking in the Top 1% for Excellence in Environmental, Social and Ethical Performance

[news]

o9 Strengthens Ties With World Economic Forum's Associate Partnership

[news]

o9 Partners with Databricks to Accelerate Time to Value for Supply Chain Planning

[news]

o9 Deploys Demand Planning at Amway 

[news]

o9 Solutions Files Trade Secret Misappropriation Complaint Against SAP and Former o9 Executives in U.S. District Court